Paclitaxel - ToLymph
Alternative Names: SMS-001Latest Information Update: 16 Dec 2024
Price :
$50 *
At a glance
- Originator ToLymph
- Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Non-small cell lung cancer
Most Recent Events
- 18 Nov 2024 Phase-II clinical trials in Non-small cell lung cancer (Adjuvant therapy) in Canada (unspecified route) (NCT06693336)
- 01 Nov 2024 Preclinical trials in Non-small cell lung cancer in Canada (unspecified route) before November 2024